Breaking News

Tweet TWEET

Media Advisory - Oncolytics Biotech® Inc. to Present at Bank of America Merrill Lynch Health Care Conference

   Media Advisory - Oncolytics Biotech® Inc. to Present at Bank of America
                     Merrill Lynch Health Care Conference

PR Newswire

CALGARY, May 14, 2013

CALGARY, May 14, 2013 /PRNewswire/ - Dr. Brad Thompson, President and CEO of
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate
overview of the Company at the Bank of America Merrill Lynch Health Care
Conference on Thursday, May 16^th, 2013 at 10:40 a.m. PT.  The conference will
take place from May 14^th to May 16^th at Encore at Wynn Las Vegas in Las
Vegas, NV.

A live audio link to the webcast presentation is available at:
http://www.veracast.com/webcasts/baml/healthcare2013/id24500830.cfm or on the
company's website at www.oncolyticsbiotech.com/presentations.  It is
recommended that listeners log on 10 minutes in advance of the presentation to
register and download any necessary software. An audio replay will be
accessible approximately one hour following the presentation on the Oncolytics
website.

About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development
of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical
program includes a variety of human trials including a Phase III trial in head
and neck cancers using REOLYSIN^®, its proprietary formulation of the human
reovirus. For further information about Oncolytics, please visit:
www.oncolyticsbiotech.com.

The presentation and webcast times are subject to change. This release and the
presentation related thereto contain forward-looking statements which  involve 
known and unknown risks, delays, uncertainties and other factors not under the
Company's  control  and  which  may  cause  actual  results,  performance   or 
achievements of  the Company  to  be materially  different from  the  results, 
performance or expectations implied by these forward-looking statements.  Such 
risks and uncertainties include, among others,  the efficacy of REOLYSIN as  a 
cancer treatment, the success  and timely completion  of clinical studies  and 
trials,  uncertainties   related   to   the  research   and   development   of 
pharmaceuticals and uncertainties related to the regulatory process. Investors
should consult the Company's  quarterly and annual  filings with the  Canadian 
and U.S.  securities  commissions  for additional  information  on  risks  and 
uncertainties  relating  to  the  forward-looking  statements.  Investors  are 
cautioned against placing  undue reliance on  forward-looking statements.  The 
Company does not undertake to update these forward-looking statements,  except 
as required by applicable laws.

SOURCE Oncolytics Biotech Inc.

Contact:

The Equicom Group
Nick Hurst
300 5^th Ave. SW, 10^th Floor
Calgary, Alberta T2P 3C4
Tel: 403.218.2835
Fax: 403.218.2830
nhurst@tmxequicom.com

Dian Griesel, Inc.
Susan Forman
396 West Broadway, 2^nd Floor
New York, NY 10012
Tel: 212.825.3210
Fax: 212.825.3229
sforman@dgicomm.com